Nifty
Sensex
:
:
23587.50
78041.59
-364.20 (-1.52%)
-1176.46 (-1.49%)

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 543064 | NSE: SUVENPHAR

1185.15
20-Dec-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1214.45
  •  1223.00
  •  1162.70
  •  1216.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  218796
  •  2615.51
  •  1360.00
  •  585.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 30,061.58
  • 123.66
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 30,028.50
  • N/A
  • 15.20

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 50.10%
  • 11.08%
  • 9.76%
  • FII
  • DII
  • Others
  • 10.7%
  • 16.66%
  • 1.70%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 4.75
  • -7.31

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 1.07
  • -6.95

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 2.24
  • -12.86

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 32.21

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 9.03

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 30.66

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
11.8
14.9
20.69
25.26
P/E Ratio
106.7
84.5
60.85
49.84
Revenue
1036
1091
1461
1705
EBITDA
406
418
642
763
Net Income
300
312
480
578
ROA
14.2
19.3
22.9
23.3
P/Bk Ratio
15.63
13.31
10.92
8.96
ROE
16.02
FCFF
301.18
547.06
587.69
777.92
FCFF Yield
0.94
1.71
1.84
2.43

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Net Sales
257.72
231.05
11.54%
230.69
347.55
-33.62%
252.93
369.36
-31.52%
219.82
353.77
-37.86%
Expenses
153.71
132.41
16.09%
150.76
179.80
-16.15%
179.59
197.49
-9.06%
154.68
207.08
-25.30%
EBITDA
104.01
98.64
5.44%
79.93
167.75
-52.35%
73.34
171.86
-57.33%
65.14
146.70
-55.60%
EBIDTM
40.36%
42.69%
34.65%
48.27%
29.00%
46.53%
29.64%
41.47%
Other Income
14.12
19.84
-28.83%
18.16
10.67
70.20%
17.05
11.40
49.56%
14.34
13.01
10.22%
Interest
1.67
1.14
46.49%
1.60
1.86
-13.98%
2.30
5.03
-54.27%
1.27
1.38
-7.97%
Depreciation
16.96
11.95
41.92%
13.40
12.61
6.26%
17.25
12.02
43.51%
12.75
12.24
4.17%
PBT
99.50
105.39
-5.59%
83.09
163.95
-49.32%
70.85
166.21
-57.37%
65.47
146.08
-55.18%
Tax
17.52
25.84
-32.20%
22.32
43.35
-48.51%
17.48
42.24
-58.62%
18.71
38.36
-51.23%
PAT
81.98
79.55
3.05%
60.77
120.60
-49.61%
53.37
123.97
-56.95%
46.75
107.72
-56.60%
PATM
31.81%
34.43%
26.34%
34.70%
21.10%
33.56%
21.27%
30.45%
EPS
3.23
3.12
3.53%
2.39
4.74
-49.58%
2.10
4.87
-56.88%
1.84
4.23
-56.50%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Net Sales
961.16
1,051.35
1,340.33
1,320.22
1,009.72
833.79
377.83
Net Sales Growth
-26.16%
-21.56%
1.52%
30.75%
21.10%
120.68%
 
Cost Of Goods Sold
271.82
311.39
402.97
394.05
297.56
225.32
101.46
Gross Profit
689.34
739.97
937.36
926.17
712.16
608.47
276.37
GP Margin
71.72%
70.38%
69.94%
70.15%
70.53%
72.98%
73.15%
Total Expenditure
638.74
645.54
766.17
738.50
566.72
449.03
206.28
Power & Fuel Cost
-
48.30
73.93
59.55
44.20
38.23
18.06
% Of Sales
-
4.59%
5.52%
4.51%
4.38%
4.59%
4.78%
Employee Cost
-
135.92
118.25
100.48
76.23
65.10
29.63
% Of Sales
-
12.93%
8.82%
7.61%
7.55%
7.81%
7.84%
Manufacturing Exp.
-
89.05
109.62
129.24
105.31
83.89
35.11
% Of Sales
-
8.47%
8.18%
9.79%
10.43%
10.06%
9.29%
General & Admin Exp.
-
35.90
33.87
28.99
27.73
25.97
12.62
% Of Sales
-
3.41%
2.53%
2.20%
2.75%
3.11%
3.34%
Selling & Distn. Exp.
-
10.35
17.64
19.80
10.53
9.43
6.72
% Of Sales
-
0.98%
1.32%
1.50%
1.04%
1.13%
1.78%
Miscellaneous Exp.
-
14.63
9.90
6.37
5.16
1.08
2.69
% Of Sales
-
1.39%
0.74%
0.48%
0.51%
0.13%
0.71%
EBITDA
322.42
405.81
574.16
581.72
443.00
384.76
171.55
EBITDA Margin
33.54%
38.60%
42.84%
44.06%
43.87%
46.15%
45.40%
Other Income
63.67
61.91
46.36
92.38
14.24
18.12
0.60
Interest
6.84
7.45
12.81
8.53
11.67
23.07
2.79
Depreciation
60.36
54.60
47.99
39.10
31.64
23.51
11.50
PBT
318.91
405.67
559.73
626.48
413.94
356.30
157.87
Tax
76.03
105.39
148.44
213.78
105.33
87.51
48.59
Tax Rate
23.84%
25.98%
26.52%
34.12%
25.45%
24.56%
30.78%
PAT
242.87
300.28
411.29
453.80
308.61
268.79
109.27
PAT before Minority Interest
243.10
300.28
411.29
453.80
308.61
268.79
109.27
Minority Interest
0.23
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
25.27%
28.56%
30.69%
34.37%
30.56%
32.24%
28.92%
PAT Growth
-43.76%
-26.99%
-9.37%
47.05%
14.81%
145.99%
 
EPS
9.54
11.79
16.15
17.82
12.12
10.56
4.29

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Shareholder's Funds
2,050.66
1,735.18
1,527.18
1,180.81
844.76
590.29
Share Capital
25.46
25.46
25.46
25.46
12.73
0.00
Total Reserves
2,023.21
1,709.73
1,501.72
1,155.35
832.03
577.56
Non-Current Liabilities
96.53
71.79
92.11
73.91
127.68
35.12
Secured Loans
0.00
4.56
28.44
35.59
0.00
0.00
Unsecured Loans
0.00
0.00
0.00
0.00
91.25
0.00
Long Term Provisions
10.50
8.30
8.89
6.65
8.31
5.95
Current Liabilities
206.06
303.09
347.52
321.51
319.85
190.67
Trade Payables
42.36
70.09
105.90
82.93
71.06
53.57
Other Current Liabilities
21.22
19.84
29.54
28.57
27.51
19.47
Short Term Borrowings
38.58
64.60
67.13
105.64
94.04
82.79
Short Term Provisions
103.90
148.56
144.94
104.36
127.24
34.83
Total Liabilities
2,353.25
2,110.06
1,966.81
1,576.23
1,292.29
816.08
Net Block
669.62
663.33
534.19
441.16
356.74
270.90
Gross Block
927.38
875.60
693.81
569.62
456.66
347.41
Accumulated Depreciation
257.76
212.27
159.62
128.46
99.91
76.51
Non Current Assets
990.90
954.70
701.66
909.68
781.17
393.28
Capital Work in Progress
179.08
165.09
29.99
96.32
101.71
111.07
Non Current Investment
130.58
117.10
117.10
361.19
307.46
0.07
Long Term Loans & Adv.
11.41
9.19
13.07
10.85
15.06
11.02
Other Non Current Assets
0.20
0.00
7.30
0.16
0.20
0.22
Current Assets
1,362.35
1,155.37
1,265.16
666.54
511.12
422.80
Current Investments
773.90
418.94
481.22
180.59
30.67
7.06
Inventories
231.20
312.81
283.42
201.08
174.87
157.10
Sundry Debtors
133.66
110.94
236.37
102.38
117.20
147.50
Cash & Bank
50.50
68.01
47.31
9.65
14.07
12.90
Other Current Assets
173.09
11.46
9.15
56.03
174.30
98.24
Short Term Loans & Adv.
161.19
233.21
207.69
116.80
134.56
37.32
Net Current Assets
1,156.29
852.28
917.64
345.04
191.27
232.13
Total Assets
2,353.25
2,110.07
1,966.82
1,576.22
1,292.29
816.08

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Cash From Operating Activity
358.48
457.20
330.00
382.55
406.92
50.40
PBT
405.67
559.73
667.59
467.67
404.51
157.87
Adjustment
15.35
37.46
40.63
36.48
34.60
13.93
Changes in Working Capital
47.41
5.77
-193.97
-12.17
54.21
-88.33
Cash after chg. in Working capital
468.43
602.96
514.26
491.98
493.33
83.47
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-109.95
-145.76
-184.26
-109.44
-86.41
-33.06
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-362.25
-195.01
-136.14
-311.40
-413.45
-65.48
Net Fixed Assets
-65.47
-154.01
-57.86
-107.57
-99.89
Net Investments
-374.60
-110.17
-173.65
-149.92
-269.19
Others
77.82
69.17
95.37
-53.91
-44.37
Cash from Financing Activity
-13.80
-241.95
-156.48
-75.66
7.32
25.98
Net Cash Inflow / Outflow
-17.57
20.24
37.38
-4.51
0.79
10.90
Opening Cash & Equivalents
64.80
44.56
7.18
11.70
10.90
0.00
Closing Cash & Equivalent
47.23
64.80
44.56
7.18
11.70
10.90

Financial Ratios

Standalone /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Book Value (Rs.)
80.48
68.16
59.99
46.39
33.18
0.00
ROA
13.46%
20.18%
25.62%
21.52%
25.50%
13.39%
ROE
15.87%
25.21%
33.52%
30.47%
37.80%
18.92%
ROCE
21.22%
33.41%
45.92%
36.19%
44.55%
23.87%
Fixed Asset Turnover
1.17
1.71
2.09
1.97
2.07
1.09
Receivable days
42.46
47.25
46.80
39.69
57.94
142.49
Inventory Days
94.43
81.11
66.93
67.95
72.66
151.76
Payable days
65.90
79.70
87.45
94.44
49.88
86.75
Cash Conversion Cycle
70.98
48.66
26.27
13.19
80.72
207.50
Total Debt/Equity
0.02
0.04
0.06
0.12
0.22
0.14
Interest Cover
55.44
44.69
79.29
36.48
16.45
57.60

News Update:


  • Suven Pharmaceuticals acquires 56% stake in NJ Bio
    21st Dec 2024, 18:01 PM

    The acquisition of 56% equity share capital of NJ Bio by the company has been completed on December 20, 2024

    Read More
  • Suven Pharmaceuticals to acquire controlling stake in NJ Bio
    7th Dec 2024, 17:29 PM

    This acquisition positions the company as a key player in one of the fastest growing segments of the Pharma CDMO landscape

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.